Ficlatuzumab Biosimilar - Research Grade

Human

HGF

>1mg/ml

Human IgG1 Kappa

Rilotumumab Biosimilar - Research Grade (ICH5110), Umikibart Biosimilar - Research Grade (ICH5956)

https://www.imgt.org/mAb-DB/

ICH3002

P14210

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of ficlatuzumab, provided for research use only. Ficlatuzumab is a humanized IgG1 kappa antibody directed against human hepatocyte growth factor (HGF), the ligand for the MET receptor tyrosine kinase. By binding HGF, the analog neutralizes ligand-driven activation of MET signaling, making it a useful tool for interrogating the HGF/MET axis in vitro and in preclinical models. Because it reproduces the binding specificity of the originator without being formulated or intended for clinical use, it serves well as a positive control, a benchmarking reagent for assay development, a neutralizing antibody in cell-based signaling studies, and a starting point for ADCC or antibody-drug-conjugate development workflows. It is supplied as bulk material at milligram-to-gram scale with low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg), suitable for demanding functional assays. It is not the clinical drug and is not for human or veterinary use. Hepatocyte growth factor (HGF, UniProt P14210), also called scatter factor, is a multidomain glycoprotein secreted mainly by mesenchymal and stromal cells. It is produced as an inactive single-chain precursor that is proteolytically cleaved into a disulfide-linked alpha/beta heterodimer to become active. HGF is the sole high-affinity ligand for the receptor tyrosine kinase MET (c-Met). Ligand binding drives MET dimerization, autophosphorylation, and downstream signaling through PI3K/AKT, RAS/MAPK, and STAT3 pathways, promoting cell proliferation, survival, motility (scattering), morphogenesis, and angiogenesis. Physiologically the HGF/MET axis is central to tissue regeneration, wound healing, and embryonic development. Aberrant HGF/MET signaling contributes to tumor growth, invasion, metastasis, and resistance to targeted therapies, which makes HGF neutralization an actively studied intervention point in oncology research.

Hepatopoietin-A, Scatter factor, SF, Hepatocyte growth factor, HPTA

Detects human HGF

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.